Literature DB >> 19728052

The -174 G/C polymorphism in interleukin-6 (IL-6) promoter region is associated with serum IL-6 and carcinoembryonic antigen levels in patients with colorectal cancers in Taiwan.

Kun-Yun Yeh1, Ying-Ying Li, Ling-Ling Hsieh, Jim-Ray Chen, Rei-Ping Tang.   

Abstract

INTRODUCTION: We investigated the associations between -174 G/C polymorphism of interleukin-6 (IL-6) gene promoter and serum IL-6 and carcinoembryonic antigen (CEA) levels in Taiwanese patients with colorectal cancer (CRC). RESULTS AND DISCUSSION: The frequency of the G allele was only 0.043, which is significantly lower compared to Western analogs. On grouping genotypes as G-positive (GG and CG) and G-negative (GG), the average IL-6 level and CEA levels were significantly lower in G-positive patients than in G-negative analogs (IL-6, 3.56 +/- 4.38 vs. 15.38 +/- 9.52 pg/ml, P = 0.021; CEA, 27.7 +/- 25.7 vs. 157.7 +/- 59.6 ng/ml, P = 0.012). The patients without the G allele had higher incidences of synchronous cancers of other origins (P = 0.003).
CONCLUSION: In conclusion, ethnicity affects the status of -174 G/C IL-6 polymorphism. This polymorphism status consequently influences the expressions of serum IL-6 and CEA and incidences of synchronous cancers of other origins.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19728052     DOI: 10.1007/s10875-009-9324-6

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  62 in total

1.  A novel NlaIII polymorphism in the human IL-6 promoter.

Authors:  O Olomolaiye; N A Wood; J L Bidwell
Journal:  Eur J Immunogenet       Date:  1998 Apr-Jun

2.  Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation.

Authors:  C F Terry; V Loukaci; F R Green
Journal:  J Biol Chem       Date:  2000-06-16       Impact factor: 5.157

3.  Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis.

Authors:  S F Shariat; B Andrews; M W Kattan; J Kim; T M Wheeler; K M Slawin
Journal:  Urology       Date:  2001-12       Impact factor: 2.649

4.  IL-6 induces neuroendocrine dedifferentiation and cell proliferation in non-small cell lung cancer cells.

Authors:  Kuo-Ting Chang; Chun-Ming Tsai; Yih-Chy Chiou; Chao-Hua Chiu; King-Song Jeng; Chi-Ying F Huang
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2005-05-13       Impact factor: 5.464

Review 5.  Mucosal and enterocyte IL-6 production during sepsis and endotoxemia--role of transcription factors and regulation by the stress response.

Authors:  Timothy Pritts; Eric Hungness; Quan Wang; Bruce Robb; Dan Hershko; Per-Olof Hasselgren
Journal:  Am J Surg       Date:  2002-04       Impact factor: 2.565

6.  The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis.

Authors:  D Fishman; G Faulds; R Jeffery; V Mohamed-Ali; J S Yudkin; S Humphries; P Woo
Journal:  J Clin Invest       Date:  1998-10-01       Impact factor: 14.808

7.  Interleukin-10 activates the transcription factor C/EBP and the interleukin-6 gene promoter in human intestinal epithelial cells.

Authors:  Bruce W Robb; Dan D Hershko; James H Paxton; Guang-Ju Luo; Per-Olof Hasselgren
Journal:  Surgery       Date:  2002-08       Impact factor: 3.982

8.  Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden.

Authors:  R Mouawad; A Benhammouda; O Rixe; E C Antoine; C Borel; M Weil; D Khayat; C Soubrane
Journal:  Clin Cancer Res       Date:  1996-08       Impact factor: 12.531

9.  Serum levels of cytokines in patients with colorectal cancer: possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis.

Authors:  T Ueda; E Shimada; T Urakawa
Journal:  J Gastroenterol       Date:  1994-08       Impact factor: 7.527

10.  Increased serum levels of interleukin-6 in malnourished patients with colorectal cancer.

Authors:  Tohru Nakagoe; Takashi Tsuji; Terumitsu Sawai; Kenji Tanaka; Shigekazu Hidaka; Shin ichi Shibasaki; Atsushi Nanashima; Masayuki Ohbatake; Hiroyuki Yamaguchi; Toru Yasutake; Kazuyuki Sugawara; Naoko Inokuchi; Shimeru Kamihira
Journal:  Cancer Lett       Date:  2003-12-08       Impact factor: 8.679

View more
  6 in total

1.  Interaction between SELP genetic polymorphisms with inflammatory cytokine interleukin-6 (IL-6) gene variants on cardiovascular disease in Chinese Han population.

Authors:  Lu Kou; Ning Yang; Bo Dong; Yang Li; Jingyu Yang; Qin Qin
Journal:  Mamm Genome       Date:  2017-08-18       Impact factor: 2.957

Review 2.  Prevention of colitis-associated cancer: natural compounds that target the IL-6 soluble receptor.

Authors:  Cate Moriasi; Dharmalingam Subramaniam; Shanjana Awasthi; Satish Ramalingam; Shrikant Anant
Journal:  Anticancer Agents Med Chem       Date:  2012-12       Impact factor: 2.505

3.  Association between the interleukin-6 promoter polymorphism -174G/C and serum lipoprotein(a) concentrations in humans.

Authors:  Heiner K Berthold; Matthias Laudes; Wilhelm Krone; Ioanna Gouni-Berthold
Journal:  PLoS One       Date:  2011-09-14       Impact factor: 3.240

4.  Association of interleukin-6 genetic polymorphisms with risk of OSCC in Indian population.

Authors:  Prithvi Kumar Singh; Girish Chandra; Jaishri Bogra; Rajni Gupta; Vijay Kumar; Amita Jain; Syed Rizwan Hussain; Abbas Ali Mahdi; Mohammad Kaleem Ahmad
Journal:  Meta Gene       Date:  2015-05-15

5.  Pretreatment serum interleukin-1β, interleukin-6, and tumor necrosis factor-α levels predict the progression of colorectal cancer.

Authors:  Pei-Hung Chang; Yi-Ping Pan; Chung-Wei Fan; Wen-Ko Tseng; Jen-Seng Huang; Tsung-Han Wu; Wen-Chi Chou; Cheng-Hsu Wang; Kun-Yun Yeh
Journal:  Cancer Med       Date:  2016-01-22       Impact factor: 4.452

6.  Interactions between vitamin D receptor (VDR) gene and Interleukin-6 gene and environment factors on coronary heart disease risk in a Chinese Han population.

Authors:  Ma Jun; Guan Xue-Qiang; Li Jia; Xue Yang-Jing; Zheng Cheng; Jin Ge
Journal:  Oncotarget       Date:  2017-07-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.